骨转移瘤及其治疗反应的分子影像学
本文综述了SPECT/CT、PET/CT及全身MRI弥散加权成像等分子与混合影像技术在骨转移瘤分期及治疗反应评估中的作用,指出这些技术较传统影像可提高诊断准确性并更早预测治疗反应,但尚未在临床常规开展,部分中心已将其纳入常规实践。
要点
- SPECT/CT、PET/CT和全身MRI可提高骨转移分期诊断准确性并更早指导个体化治疗。
- 传统影像(X线、CT、MRI、骨显像)对治疗反应监测不敏感且缺乏特异性。
- 分子与混合影像及全身MRI有望更早准确预测治疗反应,但尚未常规用于临床实践。
核心结论
- SPECT/CT、PET/CT和全身MRI等分子与混合影像技术较标准影像方法提高了骨转移分期与治疗反应评估的诊断准确性,能够量化骨微环境及肿瘤细胞相关的生物学过程。
- 这些方法的改进已使部分中心将其纳入常规临床实践,并为临床试验中评估骨转移治疗反应提供了更好的方法。
研究设计与样本
- 综述,总结SPECT/CT、PET/CT和全身MRI等新型分子与混合影像方法在骨转移分期及治疗反应评估中的作用。
主要发现
- 骨转移常见,尤其在乳腺癌和前列腺癌等更普遍的恶性肿瘤中,可导致显著疾病负担并消耗医疗资源。
- 传统影像(X线、CT、MRI和骨显像)在临床相关时间窗内对治疗反应监测被认为不敏感且缺乏特异性。
- 分子与混合影像技术及全身MRI的早期报告有望更早、更准确地预测治疗反应与无反应,但尚未被常规采用于临床实践。
临床怎么用
- 部分中心已将所描述的骨转移影像改进方法纳入常规临床实践。
- 这些方法为临床试验中评估骨转移治疗反应提供了更好的方式。
局限性
- 分子与混合影像技术及全身MRI的早期报告虽有望更早、更准确地预测治疗反应与无反应,但尚未被常规采用于临床实践。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Bone metastases are common, especially in more prevalent malignancies such as breast and prostate cancer. They cause significant morbidity and draw on health-care resources. Molecular and hybrid imaging techniques, including SPECT/CT, PET/CT, and whole-body MRI with diffusion-weighted imaging, have improved diagnostic accuracy in staging the skeleton compared with previous standard imaging methods, allowing earlier tailored treatment. With the introduction of several effective treatment options, it is now even more important to detect and monitor response in bone metastases accurately. Conventional imaging, including radiographs, CT, MRI, and bone scintigraphy, are recognized as being insensitive and nonspecific for response monitoring in a clinically relevant time frame. Early reports of molecular and hybrid imaging techniques, as well as whole-body MRI, promise an earlier and more accurate prediction of response versus nonresponse but have yet to be adopted routinely in clinical practice. We summarize the role of new molecular and hybrid imaging methods, including SPECT/CT, PET/CT, and whole-body MRI. These modalities are associated with improvements in diagnostic accuracy for the staging and response assessment of skeletal metastases over standard imaging methods, being able to quantify biologic processes related to the bone microenvironment as well as tumor cells. The described improvements in the imaging of bone metastases and their response to therapy have led to adoption of some of these methods into routine clinical practice in some centers. These methods also provide a better way to assess the treatment response of bone metastases in clinical trials.
引用
- Cook GJR, Goh V. Molecular Imaging of Bone Metastases and Their Response to Therapy. J Nucl Med. 2020. PMID: 32245899. doi:10.2967/jnumed.119.234260
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。